Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.
Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.